Emerging drugs for EGFR-mutated non-small cell lung cancer

References

• Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010 Sep 1;60(5):277–300.
   PubMed Web of Science ®Google Scholar
• Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol. 2005 Sep 1;23(25):5900–5909. PubMed PMID: 16043828.
   PubMed Web of Science ®Google Scholar
• Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009 Sep 3;361(10):958–967. PubMed PMID: 19692684.
   PubMed Web of Science ®Google Scholar
• Zhang H, Berezov A, Wang Q, et al. ErbB receptors: from oncogenes to targeted cancer therapies. J Clin Invest. 2007 Aug;117(8):2051–2058. PubMed PMID: 17671639; PubMed Central PMCID: PMC1934579.
   PubMed Web of Science ®Google Scholar
• Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001 Feb;2(2):127–137. PubMed PMID: 11252954.
   PubMed Web of Science ®Google Scholar
• Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005 Mar 2;97(5):339–346. PubMed PMID: 15741570.
   PubMed Web of Science ®Google Scholar
• Wu J-Y, Wu S-G, Yang C-H, et al. Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response. Clin Cancer Res. 2008;14(15):4877–4882.
   Web of Science ®Google Scholar
• Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004 May 20;350(21):2129–2139. PubMed PMID: 15118073.
   PubMed Web of Science ®Google Scholar
• Hsu WH, Yang JC, Mok TS, et al. Overview of current systemic management of EGFR-mutant NSCLC. Ann Oncol. 2018 Jan 1;29(suppl_1):i3–i9. PubMed PMID: 29462253.
   PubMed Web of Science ®Google Scholar
• Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3(75):75ra26.
   PubMed Web of Science ®Google Scholar
• Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239–246.
   PubMed Web of Science ®Google Scholar
• Wu YL, Zhou C, Liam CK, et al. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. Ann Oncol. 2015 Sep;26(9):1883–1889. PubMed PMID: 26105600.
   PubMed Web of Science ®Google Scholar
• Zhou C, Wu Y-L, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12(8):735–742.
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009 Sep 3;361(10):947–957. PubMed PMID: 19692680.
   PubMed Web of Science ®Google Scholar
• Yang JJ, Zhou Q, Yan HH, et al. A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations. Br J Cancer. 2017 Feb 28;116(5):568–574. PubMed PMID: 28103612; PubMed Central PMCID: PMC5344291.
   PubMed Web of Science ®Google Scholar
• Yang JC, Wu YL, Schuler M, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015 Feb;16(2):141–151. PubMed PMID: 25589191.
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Tan EH, O’Byrne K, et al. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. Ann Oncol. 2017 Feb 1;28(2):270–277. PubMed PMID: 28426106; PubMed Central PMCID: PMC5391700.
   PubMed Web of Science ®Google Scholar
• Yang JC, Sequist LV, Geater SL, et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol. 2015 Jul;16(7):830–838. PubMed PMID: 26051236.
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017 Feb 16;376(7):629–640. PubMed PMID: 27959700.
   PubMed Web of Science ®Google Scholar
• Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018 Jan 11;378(2):113–125. PubMed PMID: 29151359.
   PubMed Web of Science ®Google Scholar
• Yu HA, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013 Apr 15;19(8):2240–2247. PubMed PMID: 23470965; PubMed Central PMCID: PMC3630270.
   PubMed Web of Science ®Google Scholar
• Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005 Mar;2(3):e73. PubMed PMID: 15737014; PubMed Central PMCID: PMC549606.
   PubMed Web of Science ®Google Scholar
• Yoshimura K, Inui N, Karayama M, et al. Successful crizotinib monotherapy in EGFR-mutant lung adenocarcinoma with acquired MET amplification after erlotinib therapy. Respir Med Case Rep. 2017;20:160–163. PubMed PMID: 28271038; PubMed Central PMCID: PMC5322209. eng.
   PubMed Web of Science ®Google Scholar
• Li A, Yang JJ, Zhang XC, et al. Acquired MET Y1248H and D1246N mutations mediate resistance to MET inhibitors in non-small cell lung cancer. Clin Cancer Res. 2017 Aug 15;23(16):4929–4937. PubMed PMID: 28396313.
   PubMed Web of Science ®Google Scholar
• Gatzemeier U, Groth G, Butts C, et al. Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. Ann Oncol. 2004 Jan;15(1):19–27. PubMed PMID: 14679114.
   PubMed Web of Science ®Google Scholar
• Ohashi K, Sequist LV, Arcila ME, et al. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc Natl Acad Sci U S A. 2012 Jul 31;109(31):E2127–33. PubMed PMID: 22773810; PubMed Central PMCID: PMC3411967.
   PubMed Web of Science ®Google Scholar
• Niederst MJ, Sequist LV, Poirier JT, et al. RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. Nat Commun. 2015 Mar 11;6:6377. PubMed PMID: 25758528; PubMed Central PMCID: PMC4357281.
   PubMed Web of Science ®Google Scholar
• Della Corte CM, Bellevicine C, Vicidomini G, et al. SMO gene amplification and activation of the hedgehog pathway as novel mechanisms of resistance to anti-epidermal growth factor receptor drugs in human lung cancer. Clin Cancer Res. 2015 Oct 15;21(20):4686–4697. PubMed PMID: 26124204.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Lee JC, Lin L, et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet. 2012 Jul 1;44(8):852–860. PubMed PMID: 22751098; PubMed Central PMCID: PMC3408577.
   PubMed Web of Science ®Google Scholar
• Goss G, Tsai CM, Shepherd FA, et al. CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials. Ann Oncol. 2018 Mar 1;29(3):687–693. PubMed PMID: 29293889.
   PubMed Web of Science ®Google Scholar
• Ou SI, Agarwal N, Ali SM. High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression. Lung Cancer. 2016 Aug;98:59–61. PubMed PMID: 27393507.
   PubMed Web of Science ®Google Scholar
• Chabon JJ, Simmons AD, Lovejoy AF, et al. Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. Nat Commun. 2016 Jun 10;7:11815. PubMed PMID: 27283993; PubMed Central PMCID: PMC4906406.
   PubMed Web of Science ®Google Scholar
• Mok TS, Cheng Y, Zhou X, et al. Improvement in overall survival in a randomized study that compared Dacomitinib with gefitinib in patients with advanced non–small-cell lung cancer and EGFR-activating mutations. J clin oncol. 2018;78:7994. PubMed PMID: 29864379.
   Google Scholar
• Ma Y, Zheng X, Zhao H, et al. First-in-human phase I study of AC0010, a mutant-selective EGFR inhibitor in non-small cell lung cancer: safety, efficacy, and potential mechanism of resistance. J Thorac Oncol. 2018 Apr 4. PubMed PMID: 29626621. DOI: 10.1016/j.jtho.2018.03.025.
   Web of Science ®Google Scholar
• Xu X, Mao L, Xu W, et al. AC0010, an irreversible EGFR inhibitor selectively targeting mutated EGFR and overcoming T790M-induced resistance in animal models and lung cancer patients. Mol Cancer Ther. 2016 Nov;15(11):2586–2597. PubMed PMID: 27573423.
   PubMed Web of Science ®Google Scholar
• Daniel Shao-Weng T, James Chih-Hsin Y, Natasha BL, et al. Updated results of a phase 1 study of EGF816, a third-generation, mutant-selective EGFR tyrosine kinase inhibitor (TKI), in advanced non-small cell lung cancer (NSCLC) harboring T790M. J clin oncol. 2016;34(15_suppl):9044.
   Web of Science ®Google Scholar
• Daniel Shao-Weng T, Dong-Wan K, Natasha BL, et al. Genomic profiling of resistant tumor samples following progression on EGF816, a third generation, mutant-selective EGFR tyrosine kinase inhibitor (TKI), in advanced non-small cell lung cancer (NSCLC). J clin oncol. 2017;35(15_suppl):11506.
   Google Scholar
• Kim D-W, Tan DS-W, Aix SP, et al. Preliminary Phase II results of a multicenter, open-label study of nazartinib (EGF816) in adult patients with treatment-naïve EGFR-mutant non-small cell lung cancer (NSCLC). J clin oncol. 2018;36(15_suppl):9094.
   Web of Science ®Google Scholar
• Yang Z, Guo Q, Wang Y, et al. AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases. Sci Transl Med. 2016;8(368):368ra172.
   PubMed Web of Science ®Google Scholar
• Ahn MJ, Kim DW, Cho BC, et al. Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study. Lancet Respir Med. 2017 Nov;5(11):891–902. PubMed PMID: 29056570.
   PubMed Web of Science ®Google Scholar
• Husain H, Martins RG, Goldberg SB, et al. 1358PFirst-in-human phase I study of PF-06747775, a third-generation mutant selective EGFR tyrosine kinase inhibitor (TKI) in metastatic EGFR mutant NSCLC after progression on a first-line EGFR TKI. Ann Oncol. 2017;28(suppl_5):mdx380.060.
   Google Scholar
• Husain H, Martins R, Goldberg S, et al. P3.02b-001 phase 1 dose escalation of PF-06747775 (EGFR-T790M Inhibitor) in patients with advanced EGFRm (Del 19 or L858R±T790M) NSCLC. J Thorac Oncol. 2017;12(1):S1185.
   Web of Science ®Google Scholar
• Cho BC, Han J-Y, Kim S-W, et al. YH25448, a 3rd generation EGFR-TKI, in patients with EGFR-TKI-resistant NSCLC: phase I/II study results. J clin oncol. 2018;36(15_suppl):9033.
   Google Scholar
• Han B, Li K, Wang Q, et al. Efficacy and safety of third-line treatment with anlotinib in patients with refractory advanced non-small-cell lung cancer (ALTER-0303): a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2017;18:S3..
   PubMedGoogle Scholar
• Li K, Han B, Wang Q, et al. OS outcomes to anlotinib in patients (pts) with refractory NSCLC of both wild-type (WT) and mutant EGFR. J clin oncol. 2018;36(15_suppl):e21013.
   Google Scholar
• Doebele RC, Riely GJ, Spira AI, et al. First report of safety, PK, and preliminary antitumor activity of the oral EGFR/HER2 exon 20 inhibitor TAK-788 (AP32788) in non–small cell lung cancer (NSCLC). J clin oncol. 2018;36(15_suppl):9015.
   Web of Science ®Google Scholar
• Thress KS, Paweletz CP, Felip E, et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med. 2015 Jun;21(6):560–562. PubMed PMID: 25939061; PubMed Central PMCID: PMC4771182.
   PubMed Web of Science ®Google Scholar
• Piotrowska Z, Nagy R, Fairclough S, et al. OA 09.01 characterizing the genomic landscape of EGFR C797S in lung cancer using ctDNA next-generation sequencing. J Thorac Oncol. 2017;12(11):S1767.
   Web of Science ®Google Scholar
• Wang Z, Yang JJ, Huang J, et al. Lung adenocarcinoma harboring EGFR T790M and in trans C797S responds to combination therapy of first- and third-generation EGFR TKIs and shifts allelic configuration at resistance. J Thorac Oncol. 2017 Nov;12(11):1723–1727. PubMed PMID: 28662863.
   PubMed Web of Science ®Google Scholar
• Yang Z, Yang N, Ou Q, et al. Investigating novel resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor Osimertinib in non-small cell lung cancer patients. Clin Cancer Res. 2018 Mar 5. PubMed PMID: 29506987. DOI:10.1158/1078-0432.CCR-17-2310.
   Web of Science ®Google Scholar
• Zhang Y, Zhao J, Guo R, et al. Landscape of osimertinib resistant mutations between the two common subtypes of EGFR 19del or L858R in NSCLC. J clin oncol. 2018 May 20;36(15_suppl):12108.
   Web of Science ®Google Scholar
• Ramalingam SS, Yang JC, Lee CK, et al. Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer. J Clin Oncol. 2018 Mar 20;36(9):841–849. PubMed PMID: 28841389; eng.
   PubMed Web of Science ®Google Scholar
• Jia Y, Yun C-H, Park E, et al. Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors. Nature. 2016 May 25 online;534:129.
   PubMed Web of Science ®Google Scholar
• Günther M, Juchum M, Kelter G, et al. Lung cancer: EGFR inhibitors with low nanomolar activity against a therapy‐resistant L858R/T790M/C797S mutant. Angewandte Chemie. 2016 Aug 26;55(36):10890.
   Google Scholar
• Günther M, Lategahn J, Juchum M, et al. Trisubstituted pyridinylimidazoles as potent inhibitors of the clinically resistant L858R/T790M/C797S EGFR mutant: targeting of both hydrophobic regions and the phosphate binding site. J Med Chem. 2017 Jul 13;60(13):5613–5637.
   PubMed Web of Science ®Google Scholar
• Park H, Jung HY, Mah S, et al. Discovery of EGF receptor inhibitors that are selective for the d746‐750/T790M/C797S mutant through structure‐based de novo design. Angewandte Chemie. 2017 Jun 19;56(26):7634–7638.
   Google Scholar
• Uchibori K, Inase N, Araki M, et al. Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. Nat Commun. 2017 Mar 13;8:14768. PubMed PMID: 28287083; PubMed Central PMCID: PMC5355811.
   PubMed Web of Science ®Google Scholar
• Robichaux JP, Elamin YY, Tan Z, et al. Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer. Nat Med. 2018 May;24(5):638–646. PubMed PMID: 29686424; PubMed Central PMCID: PMC5964608.
   PubMed Web of Science ®Google Scholar
• Heymach J, Negrao M, Robichaux J, et al. OA02.06 A phase II trial of Poziotinib in EGFR and HER2 exon 20 mutant non-small cell lung cancer (NSCLC). J Thorac Oncol. 2018;13(10):S323–S324.
   PubMed Web of Science ®Google Scholar
• Janne PA, Yu HA, Johnson ML, et al. Phase 1 study of the anti-HER3 antibody drug conjugate U3-1402 in metastatic or unresectable EGFR-mutant NSCLC. J clin oncol. 2018;36(15_suppl):TPS9110.
   Web of Science ®Google Scholar
• Eberlein CA, Stetson D, Markovets AA, et al. Acquired resistance to the mutant-selective EGFR inhibitor AZD9291 is associated with increased dependence on RAS signaling in preclinical models. Cancer Res. 2015;75(12):2489.
   PubMed Web of Science ®Google Scholar
• Ho CC, Liao WY, Lin CA, et al. Acquired BRAF V600E mutation as resistant mechanism after treatment with Osimertinib. J Thorac Oncol. 2017 Mar;12(3):567–572. PubMed PMID: 27923714.
   PubMed Web of Science ®Google Scholar
• Vojnic M, Kurzatkowski C, Kubota D, et al. Acquired BRAF fusions as a mechanism of resistance to EGFR therapy. J clin oncol. 2018 May 20;36(15_suppl):12122.
   Web of Science ®Google Scholar
• Sos ML, Koker M, Weir BA, et al. PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res. 2009 Apr 15;69(8):3256–3261. PubMed PMID: 19351834; PubMed Central PMCID: PMC2849653.
   PubMed Web of Science ®Google Scholar
• Kawabata S, Mercado-Matos JR, Hollander MC, et al. Rapamycin prevents the development and progression of mutant epidermal growth factor receptor lung tumors with the acquired resistance mutation T790M. Cell Rep. 2014 Jun 26;7(6):1824–1832. PubMed PMID: 24931608; PubMed Central PMCID: PMC4110638.
   PubMed Web of Science ®Google Scholar
• Kim TM, Song A, Kim DW, et al. Mechanisms of acquired resistance to AZD9291: a mutation-selective, irreversible EGFR Inhibitor. J Thorac Oncol. 2015 Dec;10(12):1736–1744. PubMed PMID: 26473643.
   PubMed Web of Science ®Google Scholar
• Siefker-Radtke AO, Necchi A, Park SH, et al. First results from the primary analysis population of the phase 2 study of erdafitinib (ERDA; JNJ-42756493) in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRalt). J clin oncol. 2018 May 20;36(15_suppl):4503.
   Web of Science ®Google Scholar
• Joerger M, Cassier PA, Penel N, et al. Rogaratinib in patients with advanced urothelial carcinomas prescreened for tumor FGFR mRNA expression and effects of mutations in the FGFR signaling pathway. J clin oncol. 2018 May 20;36(15_suppl):4513.
   Web of Science ®Google Scholar
• Ham JS, Kim S, Kim HK, et al. Two cases of small cell lung cancer transformation from EGFR mutant adenocarcinoma during AZD9291 treatment. J Thorac Oncol. 2016;11(1):e1–e4.
   PubMed Web of Science ®Google Scholar
• Costa C, Molina MA, Drozdowskyj A, et al. The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial. Clin Cancer Res. 2014 Apr 1;20(7):2001–2010. PubMed PMID: 24493829.
   PubMed Web of Science ®Google Scholar
• Furuya N, Fukuhara T, Saito H, et al. Phase III study comparing bevacizumab plus erlotinib to erlotinib in patients with untreated NSCLC harboring activating EGFR mutations: NEJ026. J clin oncol. 2018 May 20;36(15_suppl):9006.
   Web of Science ®Google Scholar
• Planchard D, Yu HA, Yang JC-H, et al. Efficacy and safety results of ramucirumab in combination with osimertinib in advanced T790M-positive EGFR-mutant NSCLC. J clin oncol. 2018 May 20;36(15_suppl):9053.
   Web of Science ®Google Scholar
• Blakely CM, Pazarentzos E, Olivas V, et al. NF-kappaB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer. Cell Rep. 2015 Apr 7;11(1):98–110. PubMed PMID: 25843712; PubMed Central PMCID: PMC4394036.
   PubMed Web of Science ®Google Scholar
• Yu HA, Perez L, Chang Q, et al. A phase 1/2 trial of ruxolitinib and erlotinib in patients with EGFR-mutant lung adenocarcinomas with acquired resistance to erlotinib. J Thorac Oncol. 2017 Jan;12(1):102–109. PubMed PMID: 27613527; PubMed Central PMCID: PMC5552054.
   PubMed Web of Science ®Google Scholar
• Wheeler DL, Iida M, Dunn EF. The role of src in solid tumors. Oncologist. 2009 Jul;14(7):667–678. PubMed PMID: 19581523; PubMed Central PMCID: PMC3303596.
   PubMed Web of Science ®Google Scholar
• Kanda R, Kawahara A, Watari K, et al. Erlotinib resistance in lung cancer cells mediated by integrin beta1/Src/Akt-driven bypass signaling. Cancer Res. 2013 Oct 15;73(20):6243–6253. PubMed PMID: 23872583.
   PubMed Web of Science ®Google Scholar
• Gold KA, Lee JJ, Harun N, et al. A phase I/II study combining erlotinib and dasatinib for non-small cell lung cancer. Oncologist. 2014 Oct;19(10):1040–1041. PubMed PMID: 25170013; PubMed Central PMCID: PMC4201000.
   PubMed Web of Science ®Google Scholar
• Karachaliou N, Chaib I, Cardona Zorrilla AF, et al. AXL and CDCP1: A roadmap of innate resistance in EGFR mutant NSCLC. J clin oncol. 2018 May 20;36(15_suppl):e24003.
   Web of Science ®Google Scholar
• Gainor JF, Shaw AT, Sequist LV, et al. EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis. Clin Cancer Res. 2016 Sep 15;22(18):4585–4593. PubMed PMID: 27225694; PubMed Central PMCID: PMC5026567.
   PubMed Web of Science ®Google Scholar
• Ahn MJ, Yang J, Yu H, et al. 136O: osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: results from the TATTON phase Ib trial. J Thorac Oncol. 2016 Apr;11(4Suppl):S115. PubMed PMID: 27198274.
   PubMedGoogle Scholar
• Lee CK, Man J, Lord S, et al. Checkpoint inhibitors in metastatic EGFR-mutated non-small cell lung cancer-a meta-analysis. J Thorac Oncol. 2017 Feb;12(2):403–407. PubMed PMID: 27765535.
   PubMed Web of Science ®Google Scholar
• Lisberg A, Cummings A, Goldman JW, et al. A phase II study of Pembrolizumab in EGFR-mutant, PD-L1+, tyrosine kinase inhibitor naive patients with advanced NSCLC. J Thorac Oncol. 2018 Aug;13(8):1138–1145. PubMed PMID: 29874546; PubMed Central PMCID: PMC6063769.
   PubMed Web of Science ®Google Scholar
• Garassino MC, Cho BC, Kim J-H, et al. Durvalumab in ≥ 3rd-line advanced NSCLC: updated results from the phase 2 ATLANTIC study. J clin oncol. 2018;36(15_suppl):9058.
   Web of Science ®Google Scholar
• Nakamura A, Inoue A, Morita S, et al. Phase III study comparing gefitinib monotherapy (G) to combination therapy with gefitinib, carboplatin, and pemetrexed (GCP) for untreated patients (pts) with advanced non-small cell lung cancer (NSCLC) with EGFR mutations (NEJ009). J clin oncol. 2018;36(15_suppl):9005.
   Web of Science ®Google Scholar
• Han B, Jin B, Chu T, et al. Combination of chemotherapy and gefitinib as first-line treatment for patients with advanced lung adenocarcinoma and sensitive EGFR mutations: A randomized controlled trial. Int J Cancer. 2017 Sep 15;141(6):1249–1256. PubMed PMID: 28560853; eng.
   PubMed Web of Science ®Google Scholar
• Okada M, Tanaka K, Asahina H, et al. Safety analysis of an open label, randomized phase 2 study of osimertinib alone versus osimertinib plus carboplatin-pemetrexed for patients with non–small cell lung cancer (NSCLC) that progressed during prior epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy and which harbors a T790M mutation of EGFR. J clin oncol. 2018;36(15_suppl):e21073.
   Web of Science ®Google Scholar
• Arulananda S, Do H, Musafer A, et al. Combination osimertinib and gefitinib in C797S and T790M EGFR-mutated non-small cell lung cancer. J Thorac Oncol. 2017 Nov;12(11):1728–1732. PubMed PMID: 28843359; eng.
   PubMed Web of Science ®Google Scholar
• Jamal-Hanjani M, Wilson GA, McGranahan N, et al. Tracking the evolution of non-small-cell lung cancer. N Engl J Med. 2017 Jun 1;376(22):2109–2121. PubMed PMID: 28445112.
   PubMed Web of Science ®Google Scholar
• Suda K, Murakami I, Sakai K, et al. Heterogeneity in resistance mechanisms causes shorter duration of epidermal growth factor receptor kinase inhibitor treatment in lung cancer. Lung Cancer. 2016 Jan;91:36–40. PubMed PMID: 26711932.
   PubMed Web of Science ®Google Scholar
• Oxnard GR, Paweletz CP, Kuang Y, et al. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer Res. 2014 Mar 15;20(6):1698–1705. PubMed PMID: 24429876; PubMed Central PMCID: PMC3959249.
   PubMed Web of Science ®Google Scholar
• Sorensen BS, Wu L, Wei W, et al. Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib. Cancer. 2014 Dec 15;120(24):3896–3901. PubMed PMID: 25103305; PubMed Central PMCID: PMC4303984.
   PubMed Web of Science ®Google Scholar
• Tricker EM, Xu C, Uddin S, et al. Combined EGFR/MEK inhibition prevents the emergence of resistance in egfr-mutant lung cancer. Cancer Discov. 2015 Sep;5(9):960–971. PubMed PMID: 26036643; PubMed Central PMCID: PMC4824006.
   PubMed Web of Science ®Google Scholar
• Jonsson VD, Blakely CM, Lin L, et al. Novel computational method for predicting polytherapy switching strategies to overcome tumor heterogeneity and evolution. Sci Rep. 2017 Mar 13;7:44206. PubMed PMID: 28287179; PubMed Central PMCID: PMC5347024.
   PubMed Web of Science ®Google Scholar